Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymorphisms of the UCP2 gene have been associated with diabetes and obesity because UCP2 is involved in energy expenditure and insulin secretion.
|
31330574 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these data suggest that miR-214 regulates diabetes through a ROS/Akt/mTOR signaling pathway by UCP2 in proximal tubular cells.
|
30988734 |
2019 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our results shed further light on the regulatory network in β-cells consisting of miRNAs, UCP2, and insulin and provide novel therapeutic targets for diabetes.
|
30007975 |
2018 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, rs659366-AA at UCP2 and rs15673-TT at UCP3 were correlated to diabetes in a small sub-group of patients.
|
28281015 |
2017 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Decreased UCP2 gene expression in mononuclear cells from obese and diabetic patients might contribute to the immunological abnormalities in these metabolic disorders and suggests its role as a candidate gene in future studies of obesity and diabetes.
|
29151065 |
2017 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our aims are to evaluate the interaction between LTL and UCP2 polymorphisms in 950 subjects without diabetes.
|
27615599 |
2016 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mitochondrial protective gene PGC-1α is also closely related to diabetes, and UCP2 is related to anti-mitochondrial oxidative stress, but the mechanism of action of these genes is unclear.
|
26315270 |
2015 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
UCP2 has been shown to play an important role in obesity and diabetes.
|
24440978 |
2013 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the role of UCP2 in endothelial dysfunction associated with diabetes and obesity is unclear.
|
22461387 |
2012 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
UCP2 -866G>A (rs659366) has been implicated in cardiometabolic disease and represents a novel candidate gene for beta-blocker response, particularly among patients with diabetes.
|
20145583 |
2010 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The impact of UCP2 polymorphisms on diabetes and obesity is still under debate.
|
20804304 |
2010 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review summarizes data supporting the roles of UCP2 and UCP3 in energy dissipation, as well as the genetic variety association with fat metabolism, obesity and diabetes in humans.
|
19413708 |
2009 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A variant in the promoter of the human uncoupling protein 2 (UCP2) gene, the G-866A polymorphism, has been associated with future risk of coronary heart disease events, in those devoid of traditional risk factors and in those suffering from diabetes.
|
19527523 |
2009 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We explored the associations of three variants in the uncoupling protein 2 (UCP2) gene, one variant in the UCP2-UCP3 intergenic region and five variants in the uncoupling protein 3 (UCP3) gene with obesity and diabetes related traits in subjects with impaired glucose tolerance participating in Finnish Diabetes Prevention Study.
|
19769793 |
2009 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest a role of UCP2-UCP3 gene cluster haplotypes in diabetes; in particular, the effects of the high-risk haplotypes were more apparent in overweight Caucasian women.
|
18223008 |
2008 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lack of association between uncoupling protein-2 Ala55Val polymorphism and incident diabetes in the atherosclerosis risk in communities study.
|
18496642 |
2008 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
UCP-2 can possibly modify atherosclerotic processes initiated in vascular cells and agents that increase UCP-2 expression in vascular cells may help prevent the development and progression of atherosclerosis in patients with diabetes or hypertension.
|
17462780 |
2007 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Functional promoter variants UCP2 and UCP3 increase the prospective risk of diabetes.
|
16644712 |
2006 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pathological UCP2 expression or activation may suppress glucose-stimulated insulin secretion to the extent that diabetes onset is hastened.
|
17052202 |
2006 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The VV genotype of the UCP2 polymorphism was positively related to diabetes.
|
15951317 |
2005 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
UCP2 expression levels have been linked to predisposition to diabetes and obesity.
|
16021520 |
2005 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that agents increasing UCP-2 expression in vascular cells may help prevent the development and progression of atherosclerosis in patients with diabetes and hypertension.
|
15827742 |
2005 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We also tested for an effect of the P12A variant of the peroxisomal proliferator-activated receptor-gamma 2 (PPAR gamma 2) gene on diabetes risk given by the UCP2 SNP.
|
15562023 |
2005 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that the -866A/A genotype of the UCP2 gene may contribute to diabetes susceptibility by affecting insulin sensitivity.
|
15220218 |
2004 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To test this hypothesis we searched for association between the A-->G (-3862) variant in UCP1, the insertion/deletion (I/D) polymorphism in exon 8 in UCP2, and the C-->T (-55) polymorphism in UCP3 and diabetic nephropathy in 218 diabetic patients with normal urinary albumin excretion rate (AER), 216 with micro- or macroalbuminuria, and in 106 control subjects without a family history of diabetes.
|
15120704 |
2004 |